Aristeia Capital’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Aristeia Capital’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.63K	Hold	236,546	–	–	﹤0.01%	774
2026 Q1	$5.05K	Hold	236,546	–	–	﹤0.01%	686
2025 Q4	$6.29K	Hold	236,546	–	–	﹤0.01%	595
2025 Q3	$8.34K	Hold	236,546	–	–	﹤0.01%	518
2025 Q2	$9.78K	Hold	236,546	–	–	﹤0.01%	463
2025 Q1	$16.5K	Sell	236,546 -5,628	-2%	-$343	﹤0.01%	391
2024 Q4	$9.9K	Hold	242,174	–	–	﹤0.01%	360
2024 Q3	$12.3K	Buy	+242,174	New	+$14K	﹤0.01%	319

Other funds holding SLXNW

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.46% 1-Year Est. Return

Aristeia Capital's SLXNW Position: Q2 2026 in Review

Aristeia Capital held its Silexion Therapeutics Warrant (SLXNW) position steady in Q2 2026 at 236,546 shares worth $6.63K. The position accounts for ﹤0.01% of the portfolio, ranked #774.

Aristeia Capital first reported a position in SLXNW in Q3 2024 and has held it in 8 quarters since. The position peaked at $16.5K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q2 2026.

Aristeia Capital held 236,546 shares of Silexion Therapeutics Warrant worth $6.63K as of Q2 2026.
Aristeia Capital left its Silexion Therapeutics Warrant share count unchanged in Q2 2026.
Silexion Therapeutics Warrant made up ﹤0.01% of Aristeia Capital's portfolio in Q2 2026, its #774 holding.
Aristeia Capital first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 8 quarters since.
Aristeia Capital's Silexion Therapeutics Warrant position peaked at $16.5K in Q1 2025.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.